These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 10700659)
21. Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization. David HN; Ansseau M; Lemaire M; Abraini JH Biol Psychiatry; 2006 Jul; 60(1):49-57. PubMed ID: 16427030 [TBL] [Abstract][Full Text] [Related]
22. [Receptor antagonist of NMDA and animal models of schizophrenia]. Bian SZ; Zhang J; Liu WL; Sun ZH; Gu ZL; Jiang XG Fa Yi Xue Za Zhi; 2009 Dec; 25(6):443-6. PubMed ID: 20225623 [TBL] [Abstract][Full Text] [Related]
23. CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors. Tzavara ET; Degroot A; Wade MR; Davis RJ; Nomikos GG Eur Neuropsychopharmacol; 2009 Mar; 19(3):196-204. PubMed ID: 19116182 [TBL] [Abstract][Full Text] [Related]
24. Impact of metyrapone on MK-801-induced alterations in the rat dopamine D1 receptors. Czyrak A; Maćkowiak M; Fijał K; Chocyk A; Wedzony K Pol J Pharmacol; 1997; 49(5):305-16. PubMed ID: 9566029 [TBL] [Abstract][Full Text] [Related]
25. Dizocilpine, ketamine and ethanol reverse NMDA-induced EEG changes and convulsions in rats and mice. Sharma AC; Thorat SN; Nayar U; Kulkarni SK Indian J Physiol Pharmacol; 1991 Apr; 35(2):111-6. PubMed ID: 1838740 [TBL] [Abstract][Full Text] [Related]
26. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine]. Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L Encephale; 2001; 27(1):53-9. PubMed ID: 11294039 [TBL] [Abstract][Full Text] [Related]
27. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Depoortère R; Dargazanli G; Estenne-Bouhtou G; Coste A; Lanneau C; Desvignes C; Poncelet M; Heaulme M; Santucci V; Decobert M; Cudennec A; Voltz C; Boulay D; Terranova JP; Stemmelin J; Roger P; Marabout B; Sevrin M; Vigé X; Biton B; Steinberg R; Françon D; Alonso R; Avenet P; Oury-Donat F; Perrault G; Griebel G; George P; Soubrié P; Scatton B Neuropsychopharmacology; 2005 Nov; 30(11):1963-85. PubMed ID: 15956994 [TBL] [Abstract][Full Text] [Related]
28. Dizocilpine (MK-801), ketamine and phencyclidine: low doses affect brain field potentials in the freely moving rat in the same way as activation of dopaminergic transmission. Dimpfel W; Spüler M Psychopharmacology (Berl); 1990; 101(3):317-23. PubMed ID: 2163537 [TBL] [Abstract][Full Text] [Related]
29. The phencyclidine (PCP) analog N-[1-(2-benzo(B)thiophenyl) cyclohexyl]piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801. Koek W; Colpaert FC; Woods JH; Kamenka JM J Pharmacol Exp Ther; 1989 Sep; 250(3):1019-27. PubMed ID: 2674416 [TBL] [Abstract][Full Text] [Related]
30. Involvement of N-methyl-D-aspartate receptor stimulation in the ventral tegmental area and amygdala in behavioral sensitization to cocaine. Kalivas PW; Alesdatter JE J Pharmacol Exp Ther; 1993 Oct; 267(1):486-95. PubMed ID: 8229779 [TBL] [Abstract][Full Text] [Related]
31. Effects of MK-801 and ketamine on short-term memory deficits in passive avoidance step-down task paradigm in mice. Sharma AC; Kulkarni SK Methods Find Exp Clin Pharmacol; 1991 Apr; 13(3):155-9. PubMed ID: 1828849 [TBL] [Abstract][Full Text] [Related]
32. NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. Adams BW; Bradberry CW; Moghaddam B Synapse; 2002 Jan; 43(1):12-8. PubMed ID: 11746729 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Seillier A; Giuffrida A Behav Brain Res; 2009 Dec; 204(2):410-5. PubMed ID: 19716985 [TBL] [Abstract][Full Text] [Related]
34. Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Dedeurwaerdere S; Wintmolders C; Straetemans R; Pemberton D; Langlois X Psychopharmacology (Berl); 2011 Mar; 214(2):505-14. PubMed ID: 21057775 [TBL] [Abstract][Full Text] [Related]
35. Inhibition by noncompetitive NMDA receptor antagonists of apomorphine-induced climbing behavior in mice. Kim HS; Rhee GS; Jung JY; Lee JH; Jang CG; Park WK Life Sci; 1996; 58(17):1397-402. PubMed ID: 8622565 [TBL] [Abstract][Full Text] [Related]
36. Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. Duncan GE; Johnson KB; Breese GR J Neurosci; 1993 Sep; 13(9):3932-43. PubMed ID: 8366353 [TBL] [Abstract][Full Text] [Related]